Vicore Pharma AB
Professor Bertil E. Lindmark MD, PhD, currently serves as Chief Medical Officer at Vicore Pharma AB and Chairman of the Board at AQILION AB, while also holding board positions at ALK and Cellevate AB. With extensive experience in medical and scientific leadership across various organizations, Lindmark has previously held roles as Chief Medical Officer at Galecto, Inc., and eTheRNA immunotherapies, along with significant positions at ASLAN Pharmaceuticals and Almirall. Lindmark's academic contributions include a professorship in Innovation and Entrepreneurship at the Faculty of Medicine, Gothenburg University. Lindmark's educational background includes a Doctor of Medicine and a Doctor of Philosophy from Lund University, as well as completion of the Advanced Management Program at INSEAD.
This person is not in any teams
This person is not in any offices
Vicore Pharma AB
1 followers
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.